![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
August 16, 2022
June 21, 2022
Reflections on the spring conference season, including highlights from the Spring Group Meeting and ASCO's Annual Meeting
June 21, 2022
This single-arm phase 2 study aims to rid patients of residual disease following initial treatment
June 21, 2022
This study seeks to determine if neoadjuvant treatment with durvalumab and chemotherapy improves patient outcomes over chemotherapy alone
June 21, 2022
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
April 15, 2022
Congress creates a new health care research agency; NCI-MATCH continues to offer treatment options; ECOG-ACRIN plans for first in-person Group Meeting since 2019
January 26, 2022
Hopes for a return to normalcy in 2022—plus, recent qualitative research identifies surprising barriers to the long-term control of breast cancer
January 26, 2022
This phase 2/3 study is exploring new treatment approaches for patients with recurrent and metastatic head and neck squamous cell carcinoma
January 26, 2022
January 26, 2022
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
December 22, 2021
The co-chairs reflect on key 2021 accomplishments, and share their thanks and best wishes for a happy New Year
December 22, 2021
This observational study aims to assess the effects of the pandemic as a barrier to enrollment in the TMIST breast cancer screening trial